The clinical performance is complex and often involves multiple systems. Early identification and standardized clinical care are essential for improving prognosis. The diagnosis of this disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can help align domestic and foreign experts and teams to provide accurate diagnosis and treatment plans. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immune diseases that were previously difficult to treat have been significantly improved. Treatment needs to be closely monitored for efficacy and adverse reactions, adapted to timely regimens according to changes in conditions.
Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of lupus IV. The platform serves China's international medical service system, a team of nationally authoritative experts in the field of autoimmune and rheumatic immunity, providing the following services to patients: 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.